Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The anti-PDZ antibody is an experimental monoclonal antibody designed to target the PDZ domain of Tax-interacting protein 1 (TIP-1). TIP-1 is a radiation-inducible protein that translocates to the surface of cancer cells following irradiation, where it plays a significant role in cell signaling and survival pathways. By binding to the PDZ domain, the antibody inhibits the AKT/mTOR signaling pathway, leading to proliferation arrest and increased apoptosis in tumor cells. Preclinical studies conducted at Washington University in St. Louis have demonstrated its efficacy in lung cancer and glioblastoma models, particularly when used in combination with radiotherapy to enhance treatment outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-PDZ antibody.